Capecitabine

Capecitabine is an antimetaboite antineoplastic (anticancer) drug,which is metabolised to fluorouracil. Capecitabine is given by mouth and used as amonotherapy for metastatic colorectal carcinoma. Capecitabine is also licensed for second line treatment of locally advanced or metastatic breast cancer either in combination ao alone.

Brands
XELODA
Adult Dose
Dose: 1.25 g/m2
Single Dose: 1.2 (1.25)
Frequency: 12 hourly
Route: PO
Instructions: For 14 days. Subsequent courses repeated after 7-day interval.
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin. . The Molecular Weight of Capecitabine is 359.40.
Contraindications
Capecitabine
Effects
The severe or irreversible adverse effects of Capecitabine, which give rise to further complications include Thrombocytopenia, Hyperbilirubinemia.The symptomatic adverse reactions produced by Capecitabine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Fatigue, Nausea, Vomiting, Anorexia, Diarrhea, Fever, Constipation, Abdominal pain, Erythema, StomatitisX, Dermatitis, Eye irritation, Paresthesias, Desquamation of hands.
Indications
Capecitabine is primarily indicated in conditions like Breast cancer, Metastatic, Metastatic colorectal cancer.
Interactions
Capecitabine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementLacosamideTorasemideCapecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Capecitabine is initiated, discontinued or dose changed.VORICONAZOLECapecitabine may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of calcitriol if voriconazole is initiated, discontinued or dose changed. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Avoid use in patient with a history of hypersensitivity to capecitabine, fluorouracil or any component. It is classified as pregnancy category D and should be used only when the benefit of therapy outweigh the risk to fetus.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.